Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty

Sponsor
Henry Ford Health System (Other)
Overall Status
Completed
CT.gov ID
NCT02980926
Collaborator
(none)
32
1
2
3
10.8

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if a shorter-acting spinal anesthetic called mepivacaine has advantages over a longer-acting medication called bupivacaine.

Detailed Description

Different medications last for different amounts of time and can be changed depending on the length of the procedure. A short acting spinal is generally used for procedures lasting less than 90 minutes. A longer acting medication would be any that lasts longer than 90 minutes. These medications not only block the signals that travel along the pain nerves, they also prevent the signals that tell the patients muscles to move. This means that after a total knee replacement a patient may delayed in their ability to get up and start walking early after surgery. Walking early in the recovery has been shown to decrease the rate of pulmonary embolism and death. Ambulating early is also important to prevent loss of strength, constipation, pneumonia and urinary retention.

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty, a Randomized Controlled Clinical Trial
Actual Study Start Date :
Dec 1, 2016
Actual Primary Completion Date :
Mar 1, 2017
Actual Study Completion Date :
Mar 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mepivacaine Spinal Anesthetic

Mepivacaine 3 mL intrathecal injection of 2% solution

Drug: Mepivacaine
This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
Other Names:
  • CAS Number: 96-88-8
  • Carbocaine
  • Active Comparator: Bupivacaine Spinal Anesthetic

    Bupivacaine 12 mg of 8.25% solution

    Drug: Bupivacaine
    This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
    Other Names:
  • Sensorcaine
  • Marcaine
  • CAS 38396-39-3
  • Outcome Measures

    Primary Outcome Measures

    1. Return of motor and sensory function [Exams will take place in 15 minute intervals beginning with arrival to the PACU and will be continued for a maximum of 6 hours or until the exam returns to baseline for 2 consecutive exams.]

      Times will be recorded in minutes from the administration of the spinal anesthetic. Normal exam will include intact sensation to light touch of the thigh, calf, foot and toes. Normal motor is defined as ability to perform a straight leg raise, active knee flexion, as well as wiggling of the ankle and toes.

    Secondary Outcome Measures

    1. Pain [Entire hospital admission. No data will be recorded after 96 hours.]

      visual analog scale from 0 - 10

    2. Pain [Hospital admission, maximum of 96 hours.]

      morphine equivalent consumption

    3. Time to urination [24 hours maximum from time of spinal.]

      The total time between the administration of spinal anesthesia to the first episode of spontaneous urination will be recorded. Patients who require greater than 6 hours to urinate independently are followed per hospital protocol with serial bladder scans and straight catheterization for urinary retention as needed. Patients who exceed 6 hours to urinate will be defined as having urinary retention.

    4. Urinary retention [Entire hospital stay beginning immediately in the post operative period until discharge to a maximum of 96 hours.]

      The number of straight catheterization and foley placements will be recorded as well.

    5. Length of stay [Hospital admission maximum of 96 hours.]

      Length of stay

    6. Time to discharge readiness. [Hospital admission maximum of 96 hours.]

      Time from admission to discharge readiness as assessed by physical therapy.

    7. Transient Neurologic Symptoms [Hospital admission and first follow up visit. Data will not be recorded after 3 weeks from time of spinal]

      Any episodes of transient radiating pain in the buttocks and thigh will be recorded in the hospital charts during routine post operative rounds. This is also be discussed at the first follow up visit scheduled 2 weeks after surgery.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Adult patients undergoing primary total knee arthroplasty
    Exclusion Criteria:
    • Chronic opioid users

    • Unable to give informed consent

    • Forego the use of a foley catheter

    • Those with hypersensitively to amide local anesthetics or opioids

    • Those with contraindications to spinal anesthesia

    • Conversion to general anesthesia will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Henry Ford West Bloomfield West Bloomfield Township Michigan United States 48322

    Sponsors and Collaborators

    • Henry Ford Health System

    Investigators

    • Principal Investigator: Jason Davis, MD, Surgeon

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    M. Chad Mahan, M.D., PGY-3, Henry Ford Health System
    ClinicalTrials.gov Identifier:
    NCT02980926
    Other Study ID Numbers:
    • #10455
    First Posted:
    Dec 2, 2016
    Last Update Posted:
    Mar 27, 2017
    Last Verified:
    Mar 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 27, 2017